Myocardial Late Gadolinium Enhancement (LGE) in Cardiac Magnetic Resonance Imaging (CMR)-An Important Risk Marker for Cardiac Disease

Overview

Journal J Cardiovasc Dev Dis

Specialty Cardiology & Vascular Diseases

Date 2024 Feb 23

PMID 38392254

Authors

Claudia Meier

Michel Eisenblatter

Stephan Gielen

Affiliations

Soon will be listed here.

Abstract

Cardiovascular magnetic resonance (CMR) has significantly revolutionized the comprehension and diagnosis of cardiac diseases, particularly through the utilization of late gadolinium enhancement (LGE) imaging for tissue characterization. LGE enables the visualization of expanded extracellular spaces in conditions such as fibrosis, fibrofatty tissue, or edema. The growing recognition of LGE's prognostic capacity underscores its importance, evident in the increasing explicit recommendations within guidelines. Notably, the contemporary characterization of cardiomyopathies relies on LGE-based scar assessment by CMR to a large extent. This review describes the pattern and prognostic value of LGE in detail for various cardiac diseases. Despite its merits, establishing LGE as a reliable risk marker encounters challenges. Limitations arise from the fact that not all diseases show LGE, and it should always be analyzed in the context of all CMR sequences and the patient's medical history. In summary, LGE stands as a robust indicator of adverse outcomes in diverse cardiovascular diseases. Its further integration into routine practice is desirable, necessitating widespread availability and application to accumulate both individual and scientific experience.

Citing Articles

Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature Review.

Muglu H, Sunger E, Koylu B, Tunali D, Erol C, Selcukbiricik F Medicina (Kaunas). 2025; 61(2).

PMID: 40005418 PMC: 11857675. DOI: 10.3390/medicina61020302.

Return-to-Play Post-Myocarditis for Athletes: To Play or Not to Play?.

Yamagata K, Malhotra A Diagnostics (Basel). 2024; 14(19).

PMID: 39410640 PMC: 11475062. DOI: 10.3390/diagnostics14192236.

Cardiac amyloidosis: A diagnostic challenge.

Al Akhali E, Alshoabi S, Hamid A, Alsultan K, Omer A, Alhammadi M Radiol Case Rep. 2024; 19(11):4730-4735.

PMID: 39228955 PMC: 11366889. DOI: 10.1016/j.radcr.2024.07.119.

References

Grani C, Eichhorn C, Biere L, Murthy V, Agarwal V, Kaneko K . Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis. J Am Coll Cardiol. 2017; 70(16):1964-1976. PMC: 6506846. DOI: 10.1016/j.jacc.2017.08.050. View

Disertori M, Rigoni M, Pace N, Casolo G, Mase M, Gonzini L . Myocardial Fibrosis Assessment by LGE Is a Powerful Predictor of Ventricular Tachyarrhythmias in Ischemic and Nonischemic LV Dysfunction: A Meta-Analysis. JACC Cardiovasc Imaging. 2016; 9(9):1046-1055. DOI: 10.1016/j.jcmg.2016.01.033. View

Chamling B, Vehof V, Drakos S, Weil M, Stalling P, Vahlhaus C . Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis?. Clin Res Cardiol. 2021; 110(11):1850-1854. PMC: 8325525. DOI: 10.1007/s00392-021-01916-w. View

Ferreira V, Schulz-Menger J, Holmvang G, Kramer C, Carbone I, Sechtem U . Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol. 2018; 72(24):3158-3176. DOI: 10.1016/j.jacc.2018.09.072. View

Biesbroek P, Hirsch A, Zweerink A, van de Ven P, Beek A, Groenink M . Additional diagnostic value of CMR to the European Society of Cardiology (ESC) position statement criteria in a large clinical population of patients with suspected myocarditis. Eur Heart J Cardiovasc Imaging. 2017; 19(12):1397-1407. DOI: 10.1093/ehjci/jex308. View

Holtstiege V, Meier C, Bietenbeck M, Chatzantonis G, Florian A, Kobe J . Clinical experience regarding safety and diagnostic value of cardiovascular magnetic resonance in patients with a subcutaneous implanted cardioverter/defibrillator (S-ICD) at 1.5 T. J Cardiovasc Magn Reson. 2020; 22(1):35. PMC: 7232845. DOI: 10.1186/s12968-020-00626-y. View

von Knobelsdorff-Brenkenhoff F, Schulz-Menger J . Cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology: a comprehensive summary and update. J Cardiovasc Magn Reson. 2023; 25(1):42. PMC: 10364363. DOI: 10.1186/s12968-023-00950-z. View

Florian A, Ludwig A, Stubbe-Drager B, Boentert M, Young P, Waltenberger J . Characteristic cardiac phenotypes are detected by cardiovascular magnetic resonance in patients with different clinical phenotypes and genotypes of mitochondrial myopathy. J Cardiovasc Magn Reson. 2015; 17:40. PMC: 4490728. DOI: 10.1186/s12968-015-0145-x. View

OHanlon R, Grasso A, Roughton M, Moon J, Clark S, Wage R . Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010; 56(11):867-74. DOI: 10.1016/j.jacc.2010.05.010. View

10.

Chalil S, Foley P, Muyhaldeen S, Patel K, Yousef Z, Smith R . Late gadolinium enhancement-cardiovascular magnetic resonance as a predictor of response to cardiac resynchronization therapy in patients with ischaemic cardiomyopathy. Europace. 2007; 9(11):1031-7. DOI: 10.1093/europace/eum133. View

11.

Jiang L, Zuo H, Liu J, Wang J, Zhang K, Zhang C . The pattern of late gadolinium enhancement by cardiac MRI in fulminant myocarditis and its prognostic implication: a two-year follow-up study. Front Cardiovasc Med. 2023; 10:1144469. PMC: 10335322. DOI: 10.3389/fcvm.2023.1144469. View

12.

Austin B, Tang W, Rodriguez E, Tan C, Flamm S, Taylor D . Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging. 2010; 2(12):1369-77. DOI: 10.1016/j.jcmg.2009.08.008. View

13.

Cadour F, Ernst O, Dacher J . Can cardiac magnetic resonance imaging be used as a screening tool for iron overload?. Diagn Interv Imaging. 2023; 104(11):519-520. DOI: 10.1016/j.diii.2023.08.004. View

14.

Chatzantonis G, Bietenbeck M, Elsanhoury A, Tschope C, Pieske B, Tauscher G . Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study. Clin Res Cardiol. 2020; 110(4):555-568. PMC: 8055632. DOI: 10.1007/s00392-020-01771-1. View

15.

Bergamaschi L, Foa A, Paolisso P, Renzulli M, Angeli F, Fabrizio M . Prognostic Role of Early Cardiac Magnetic Resonance in Myocardial Infarction With Nonobstructive Coronary Arteries. JACC Cardiovasc Imaging. 2023; 17(2):149-161. DOI: 10.1016/j.jcmg.2023.05.016. View

16.

Aquaro G, Habtemicael Y, Camastra G, Monti L, Dellegrottaglie S, Moro C . Prognostic Value of Repeating Cardiac Magnetic Resonance in Patients With Acute Myocarditis. J Am Coll Cardiol. 2019; 74(20):2439-2448. DOI: 10.1016/j.jacc.2019.08.1061. View

17.

Tao J, Duan F, Long J, Meng Q, Zhang B, Zhu Z . The Role of the Submitral Apparatus in Hypertrophic Obstructive Cardiomyopathy. J Am Soc Echocardiogr. 2022; 36(2):133-145. DOI: 10.1016/j.echo.2022.09.018. View

18.

Corrado D, Perazzolo Marra M, Zorzi A, Beffagna G, Cipriani A, De Lazzari M . Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. Int J Cardiol. 2020; 319:106-114. DOI: 10.1016/j.ijcard.2020.06.005. View

19.

Ommen S, Mital S, Burke M, Day S, Elliott P, Evanovich L . 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2021; 162(1):e23-e106. DOI: 10.1016/j.jtcvs.2021.04.001. View

20.

Zhang N, Song Y, Hua W, Hu Y, Chen L, Cai M . Left ventricular involvement assessed by LGE-CMR in predicting the risk of adverse outcomes of arrhythmogenic cardiomyopathy with ICDs. Int J Cardiol. 2021; 337:79-85. DOI: 10.1016/j.ijcard.2021.04.015. View